Koers Basilea Pharmaceutica AG Xetra
Aandelen
PK5
CH0011432447
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 182 mln. 202 mln. 187 mln. | Omzet 2025 * | 198 mln. 219 mln. 203 mln. | Marktkapitalisatie | 465 mln. 516 mln. 478 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 26 mln. 28,83 mln. 26,72 mln. | Nettowinst (verlies) 2025 * | 29 mln. 32,16 mln. 29,81 mln. | EV/omzet 2024 * | 2,86 x |
Nettoschuld 2024 * | 56,76 mln. 62,95 mln. 58,34 mln. | Nettoschuld 2025 * | 12,51 mln. 13,87 mln. 12,86 mln. | EV/omzet 2025 * | 2,42 x |
K/w-verhouding 2024 * |
18,3
x | K/w-verhouding 2025 * |
16,7
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 91,61% |
Recentste transcriptie over Basilea Pharmaceutica AG
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 59 | 01-09-14 |
Adesh Kaul
DFI | Director of Finance/CFO | 50 | 01-01-09 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 60 | 01-05-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Nicole Onetto
BRD | Director/Board Member | 71 | 27-04-17 |
Leonard Kruimer
BRD | Director/Board Member | 66 | 01-01-22 |
Director/Board Member | 69 | 09-04-13 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+16,59% | 44,87 mld. | |
-10,62% | 37,8 mld. | |
+40,49% | 37,61 mld. | |
+29,92% | 31,32 mld. | |
-9,78% | 27,4 mld. | |
+12,34% | 26,32 mld. | |
+41,53% | 14,07 mld. | |
+31,49% | 12,5 mld. | |
-7,40% | 11,23 mld. |